Cartesian Therapeutics, Inc. Business Acquisition, Pro Forma Net Income (Loss)
Cartesian Therapeutics, Inc. (RNAC) reported Business Acquisition, Pro Forma Net Income (Loss) of -$232.26 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2025-03-13
- Cartesian Therapeutics, Inc. business acquisition, pro forma net income (loss) for fiscal 2023 was -$232.26M, a 884.47% decline from fiscal 2022.
- Cartesian Therapeutics, Inc. business acquisition, pro forma net income (loss) for fiscal 2022 was $29.61M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|
| 2023-12-31 | -$232.26M 10-K · filed 2025-03-13 |
| 2022-12-31 | $29.61M 10-K · filed 2024-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |